Combination therapy versus monotherapy: a randomised study on the evolution of inflammatory parameters after ventilator associated pneumonia

Submission date 22/12/2005	Recruitment status No longer recruiting	 Prospectively registered Protocol
Registration date 11/01/2006	Overall study status Completed	 Statistical analysis plan [X] Results
Last Edited 25/09/2009	Condition category Respiratory	Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s) Scientific

Contact name Prof Pierre Damas

Contact details

General Intensive Care Department University Hospital Domaine Universitaire du Sart-Tilman Liege Belgium 4000 +32 (0)4 366 74 95 pdamas@chu.ulg.ac.be

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers N/A

Study information

Scientific Title

Study objectives Does a combination antibiotic therapy of ventilator associated pneumonia improve the inflammatory parameters faster than a monotherapy?

Ethics approval required Old ethics approval format

Ethics approval(s) Yes; 27/02/02; 2002/32

Study design Randomised unblinded comparative study

Primary study design Interventional

Secondary study design Randomised controlled trial

Study setting(s) Hospital

Study type(s) Treatment

Participant information sheet

Health condition(s) or problem(s) studied Ventilator associated pneumonia

Interventions

Comparison between treatment with cefepime alone and cefepime associated with amikacin or levofloxacin

Intervention Type Drug

Phase Not Specified

Drug/device/biological/vaccine name(s)

Cefepime, amikacin, levofloxacin

Primary outcome measure

Time course evolution of C-reactive protein (CRP) levels, temperature and leucocytosis

Secondary outcome measures

Length of ventilatory support
 Evolution of PaO2/FiO2
 Mortality

Overall study start date 01/04/2002

Completion date 31/12/2003

Eligibility

Key inclusion criteria Adult patients with ventilator associated pneumonia

Participant type(s) Patient

Age group Adult

Sex

Both

Target number of participants 150

Key exclusion criteria

Patients treated for other infection
 Immunocompromised patients
 Patients with life expectancy less than 72 hours

Date of first enrolment 01/04/2002

Date of final enrolment 31/12/2003

Locations

Countries of recruitment Belgium **Study participating centre General Intensive Care Department** Liege Belgium 4000

Sponsor information

Organisation Domaine Universitaire du Sart-Tilman (Belgium)

Sponsor details

Department of General Intensive Care University Hospital Domaine Universitaire du Sart-Tilman Liege Belgium 4000 pdamas@chu.ulg.ac.be

Sponsor type University/education

ROR https://ror.org/00afp2z80

Funder(s)

Funder type University/education

Funder Name Domaine Universitaire du Sart-Tilman (Belgium)

Results and Publications

Publication and dissemination plan Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<u>Results article</u>	results	01/01/2006		Yes	No